Researchers have discovered and validated¹ a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive² impairment or Alzheimer's disease within three years. Described in Nature Medicine published online today, the study heralds³ the potential for developing treatment strategies for Alzheimer's at an earlier stage, when therapy would be more effective at slowing or preventing onset⁴ of symptoms. It is the first known published report of blood-based biomarkers for preclinical Alzheimer's.

 

The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible.

 

"Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families and treating physicians plan for and manage the disorder," says the study's corresponding author Howard J. Federoff, MD, PhD, professor of neurology and executive vice⁵ president for health sciences at Georgetown University Medical Center.

 

There is no cure or effective treatment for Alzheimer's. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050.

 

Federoff explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer's disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process.

 

"The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention," Federoff says. "Biomarkers such as ours that define this asymptomatic（无症状的） period are critical for successful development and application of these therapeutics."

 

The study included 525 healthy participants aged⁶ 70 and older who gave blood samples upon enrolling⁷ and at various points in the study. Over the course of the five-year study, 74 participants met the criteria⁸ for either mild Alzheimer's disease (AD) or a condition known as amnestic（遗忘的） mild cognitive impairment (aMCI), in which memory loss is prominent. Of these, 46 were diagnosed upon enrollment⁹ and 28 developed aMCI or mild AD during the study (the latter group called converters).

点击收听单词发音